Saturday, June 25 2022

MONMOUTH JUNCTION, NJ, May 19, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CSTO), a leader in the treatment of life-threatening conditions in the intensive care unit and heart surgery using blood purification, announces that management will present at two upcoming in-person investor conferences.

On Monday, May 23, 2022dr. Philip ChanCEO of CytoSorbents, will present to the UBS Global Healthcare Conference 2022 to 9:15 a.m. Eastern Time. A live audio webcast will be accessible via the Link. Company management will also meet with investors at the conference.

Kathleen BlochCFO of CytoSorbents, will also present to the Jefferies Healthcare Conference on Wednesday, June 8, 2022 to 4:00 p.m. Eastern Timewith a live video webcast accessible via the Link. Management will also hold investor meetings on that day.

An archived recording of CytoSorbents’ presentations at both investor conferences will be available in the Investor Relations section of the Company’s website at Events and Presentations – Cytosorbentsand will be available for 90 days.

About CytoSorbents Corporation (NASDAQ: CSTO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in critical care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in over 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” seen in diseases common serious events that can lead to massive inflammation, organ failure and patient death. These are conditions where the risk of death can be extremely high, but there are few or no effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to postoperative complications, including multiple organ failure. More than 170,000 cumulative CytoSorb devices have been used from March, 31st, 2022. CytoSorb was originally introduced in the European Union under CE marking as the first cytokine adsorber. Additional CE mark extensions have been received for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for both ticagrelor and rivaroxaban during cardiothoracic surgery . CytoSorb has also received emergency use authorization from the US FDA for use in critically ill adult COVID-19 patients with impending or confirmed respiratory failure. The DrugSorb™-ATR antithrombotic elimination system, which is based on the same polymer technology as CytoSorb, has also received FDA Breakthrough Designation for the elimination of ticagrelor, as well as FDA Breakthrough Designation for Elimination of the direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban, in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The company has initiated two pivotal FDA-approved trials designed to support the marketing approval of DrugSorb-ATR in the United States. The first is the center for 120 patients, 30 TO START UP (Ssafe and Jtimely Aantithrombotic Rmoving house-Jicagrelor) randomized controlled trial evaluating the ability of intraoperative use of DrugSorb-ATR to reduce the risk of perioperative bleeding in patients on ticagrelor undergoing cardiothoracic surgery. The second is the center for 120 patients, 30 STAR–D (Ssafe and Jtimely Aantithrombotic Rmoving house-Ddirect oral anticoagulants) randomized controlled trial, evaluating the intraoperative use of DrugSorb–ATR to reduce the risk of perioperative bleeding in patients undergoing cardiothoracic surgery on direct oral anticoagulants, including apixaban and rivaroxaban.

CytoSorbents purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received more than $39.5 million in grants, contracts, and other non-dilutive funding from DARPA, the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH ), National Heart, Lung, and Blood Institute (NHLBI), U.S. Army, U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others . The company has numerous marketed products and products in development based on this unique blood purification technology protected by numerous issued U.S. and international patents and trademarks, and several pending patent applications, including ECOS-300CY®, CytoSorb -XL™, HemoDefend-RBC™ , HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb and others. For more information, please visit the Company’s websites at and or follow us on Facebook and Twitter.

Forward-looking statements

This press release contains forward-looking statements intended to qualify for the safe harbor rule established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlook for our business, expectations regarding the future impacts of COVID-19 or the ongoing conflict between Russia and the Ukraine, representations and assertions and are not historical facts and are generally identified by the use of terms such as “may”, “should”, “could”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “continue” and similar words, although certain forward-looking statements are expressed differently. You should be aware that the forward-looking statements contained in this press release represent the current judgment and expectations of management, but our actual results, events and performance could differ materially from those contained in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 10, 2022, as updated by the risks reported in our quarterly reports on Form 10-Q, as well as in press releases and other shareholder communications that we issue from time to time that attempt to inform interested parties of the risks. and factors that may affect our business. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by federal securities laws.

Please click to follow us on Facebook and Twitter

Contact with Investor Relations:
Terri Anne Powers
Vice President, Investor Relations
and corporate communications
(732) 482-9984
[email protected]

US Public Relations Contact:
Eric Kim
Rubenstein Public Relations
[email protected]

SOURCE CytoSorbents Corporation


Learn How to Build a Business Website: A Step-by-Step Guide


How to create a website in 5 steps

Check Also